Compare · IRTC vs WST
IRTC vs WST
Side-by-side comparison of iRhythm Holdings Inc. (IRTC) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IRTC and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $24.52B, about 6.0x IRTC ($4.06B).
- IRTC has been more active in the news (13 items in the past 4 weeks vs 1 for WST).
- IRTC has more recent analyst coverage (25 ratings vs 18 for WST).
- Company
- iRhythm Holdings Inc.
- West Pharmaceutical Services Inc.
- Price
- $123.10-1.65%
- $348.50-1.36%
- Market cap
- $4.06B
- $24.52B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2016
- News (4w)
- 13
- 1
- Recent ratings
- 25
- 18
iRhythm Holdings Inc.
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. iRhythm Technologies, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest IRTC
- iRhythm Holdings Inc. filed SEC Form 8-K: Leadership Update
- President and CEO Blackford Quentin S. was granted 48,534 shares and sold $3,348,012 worth of shares (26,859 units at $124.65), increasing direct ownership by 11% to 226,008 units (SEC Form 4) (for withholding tax)
- CBO and CLO Murphy Patrick Michael was granted 13,589 shares and sold $884,156 worth of shares (7,093 units at $124.65), increasing direct ownership by 10% to 69,699 units (SEC Form 4) to satisfy withholding tax
- EVP, Chief Risk Officer Shrishrimal Sumi was granted 9,706 shares and sold $669,641 worth of shares (5,372 units at $124.65), increasing direct ownership by 11% to 44,621 units (SEC Form 4) (withholding tax)
- CHIEF COMM & PRODUCT OFFICER Patterson Chad was granted 13,589 shares and sold $884,170 worth of shares (7,093 units at $124.65), increasing direct ownership by 12% to 62,125 units (SEC Form 4) (for withholding tax)
- CHIEF MED/SCI OFCR EVP ADVTECH Turakhia Minang sold $884,151 worth of shares (7,093 units at $124.65) and was granted 13,589 shares, increasing direct ownership by 12% to 60,116 units (SEC Form 4) to satisfy tax liability
- SEC Form 10-Q filed by iRhythm Holdings Inc.
- iRhythm Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- iRhythm Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- iRhythm to Acquire VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care
Latest WST
- SVP & Chief Financial Officer Mcmahon Robert W. converted options into 7,149 shares and covered exercise/tax liability with 3,109 shares, increasing direct ownership by 136% to 7,021 units (SEC Form 4)
- SEC Form 10-Q filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- West Declares Quarterly Dividend
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- BNP Paribas Exane initiated coverage on West Pharm with a new price target
- West to Host Second-Quarter 2026 Conference Call
- SEC Form 4 filed by Director Haugen Janet Brutschea
- West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System
- West Pharm upgraded by Barclays with a new price target